CA2730290C - Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes - Google Patents

Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes Download PDF

Info

Publication number
CA2730290C
CA2730290C CA2730290A CA2730290A CA2730290C CA 2730290 C CA2730290 C CA 2730290C CA 2730290 A CA2730290 A CA 2730290A CA 2730290 A CA2730290 A CA 2730290A CA 2730290 C CA2730290 C CA 2730290C
Authority
CA
Canada
Prior art keywords
vwf
fviii
thrombocytes
factor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2730290A
Other languages
English (en)
French (fr)
Other versions
CA2730290A1 (en
Inventor
Gerhard Dickneite
Ingo Pragst
Henrique Lessa
Thorsten Haas
Stefan Zeitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41171229&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2730290(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CA2730290A1 publication Critical patent/CA2730290A1/en
Application granted granted Critical
Publication of CA2730290C publication Critical patent/CA2730290C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2730290A 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes Active CA2730290C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008032361.6 2008-07-10
DE102008032361A DE102008032361A1 (de) 2008-07-10 2008-07-10 Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
PCT/EP2009/005027 WO2010003687A1 (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Publications (2)

Publication Number Publication Date
CA2730290A1 CA2730290A1 (en) 2010-01-14
CA2730290C true CA2730290C (en) 2017-02-07

Family

ID=41171229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730290A Active CA2730290C (en) 2008-07-10 2009-07-10 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

Country Status (13)

Country Link
US (2) US8603979B2 (enExample)
EP (1) EP2310043B2 (enExample)
JP (1) JP5653916B2 (enExample)
KR (1) KR20110043654A (enExample)
CN (1) CN102088999A (enExample)
AU (1) AU2009268289B2 (enExample)
CA (1) CA2730290C (enExample)
DE (1) DE102008032361A1 (enExample)
DK (1) DK2310043T4 (enExample)
ES (1) ES2395855T5 (enExample)
PL (1) PL2310043T5 (enExample)
RU (1) RU2563236C2 (enExample)
WO (1) WO2010003687A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244814B1 (en) * 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US8329871B2 (en) * 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP2662083A1 (en) 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN103263663B (zh) * 2013-06-08 2016-05-04 兆科药业（合肥）有限公司 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
JP7326246B2 (ja) 2017-07-07 2023-08-15 武田薬品工業株式会社 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4430205A1 (de) 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US6518482B2 (en) 1994-09-13 2003-02-11 American National Red Cross Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
FR2744918B1 (fr) 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
FI974321A0 (fi) * 1997-11-25 1997-11-25 Jenny Ja Antti Wihurin Rahasto Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
ATE430578T1 (de) 1999-12-24 2009-05-15 Chemo Sero Therapeut Res Inst Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie

Also Published As

Publication number Publication date
EP2310043B2 (en) 2022-05-18
CN102088999A (zh) 2011-06-08
JP5653916B2 (ja) 2015-01-14
US9095564B2 (en) 2015-08-04
EP2310043A1 (en) 2011-04-20
ES2395855T5 (es) 2022-09-06
KR20110043654A (ko) 2011-04-27
WO2010003687A1 (en) 2010-01-14
DK2310043T4 (da) 2022-06-20
EP2310043B1 (en) 2012-09-19
PL2310043T5 (pl) 2024-02-05
PL2310043T3 (pl) 2013-02-28
AU2009268289B2 (en) 2014-11-06
DE102008032361A1 (de) 2010-01-21
US8603979B2 (en) 2013-12-10
AU2009268289A1 (en) 2010-01-14
ES2395855T3 (es) 2013-02-15
US20110112023A1 (en) 2011-05-12
DK2310043T3 (da) 2013-01-07
RU2011104705A (ru) 2012-08-20
CA2730290A1 (en) 2010-01-14
US20140128325A1 (en) 2014-05-08
JP2011527301A (ja) 2011-10-27
RU2563236C2 (ru) 2015-09-20

Similar Documents

Publication Publication Date Title
AU2009268289B2 (en) Von Willebrand Factor or Factor VIII and von Willebrand Factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
Ghadimi et al. Perioperative management of the bleeding patient
Levy et al. Antifibrinolytic therapy and perioperative considerations
Svensson et al. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding
Moore et al. Does tranexamic acid improve clot strength in severely injured patients who have elevated fibrin degradation products and low fibrinolytic activity, measured by thrombelastography?
Ikezoe et al. Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
HU219595B (hu) Von Willebrand-faktort tartalmazó koncentrátumok alkalmazása trombózis elleni szerek és/vagy fibrinotikus szerek okozta vérzésnél antidotumként ható szer előállítására
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
Levy Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas
Levy et al. Perioperative coagulation management in the intensive care unit
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
Franchini Thrombotic complications in von Willebrand disease
Haak et al. Use of Antithrombin Concentrate in Stable Diffuse Intravascular Coagulation: A Case Report
Lutz et al. Bleeding in Uremia
Rivera Tocancipá et al. blood-Saving techniques in Surgery
Marcucci et al. 11 Hematologic Risk Assessment
Steib et al. HEMOSTATIC AGENTS: WHY, WHEN AND HOW?
Agostini et al. Blood Products, Derivates, and Prohemostatic Drugs
Huang PREOPERATIVE EVALUATION OF HEMOSTASIS Assessing the risk of perioperative bleeding is a fundamental compo-nent of the preoperative evaluation. PROCEDURAL BLEEDING RISK
Saif et al. Von Willebrand disease and pregnancy
Brenni et al. Successful ROTEM-guided treatment of traumatic haemorrhage and coagulopathy due to hyperfibrinolysis using antifibrinolytic medication and fibrinogen concentrate
Biss et al. Hematological and coagulation changes in sepsis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140707

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260616

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260616